DEVELOPMENT OF A HIGH-THROUGHPUT PROCESS FOR THE PRODUCTION OF DIAGNOSTIC MONOCLONAL ANTIBODIES (Q2035396): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Removed claims)
(‎Changed an Item: The budget was changed)
Property / budget
 
10,708.04 Euro
Amount10,708.04 Euro
UnitEuro
Property / budget: 10,708.04 Euro / rank
 
Normal rank
Property / EU contribution
 
5,354.02 Euro
Amount5,354.02 Euro
UnitEuro
Property / EU contribution: 5,354.02 Euro / rank
 
Normal rank
Property / co-financing rate
 
50.0 percent
Amount50.0 percent
Unitpercent
Property / co-financing rate: 50.0 percent / rank
 
Normal rank

Revision as of 09:06, 12 February 2022

Project Q2035396 in Italy
Language Label Description Also known as
English
DEVELOPMENT OF A HIGH-THROUGHPUT PROCESS FOR THE PRODUCTION OF DIAGNOSTIC MONOCLONAL ANTIBODIES
Project Q2035396 in Italy

    Statements

    country
    Italy
    0 references
    EU contribution
    5,354.02 Euro
    0 references
    budget
    10,708.04 Euro
    0 references
    co-financing rate
    50.0 percent
    0 references
    start time
    15 November 2016
    0 references
    end time
    7 December 2018
    0 references
    expected end time
    3 December 2018
    0 references
    beneficiary name (string)
    TAKIS SRL
    0 references
    beneficiary
    Q277533
    0 references
    programme
    Lazio - ERDF
    0 references
    coordinate location

    41°53'35.95"N, 12°28'58.55"E
    0 references
    summary
    L'AZIENDA DI BIOTECNOLOGIE TAKIS PRODUCE IN MODO INNOVATIVO ED EFFICACE ANTICORPI MONOCLONALI PER CONTO PROPRIO E PER CONTO TERZI. SEBBENE MOLTO COMPETITIVA NEI PROTOCOLLI DI VACCINAZIONE, IL PROCESSO ATTUALE MANCA DI UN SISTEMA ROBOTIZZATO PER L (Italian)
    0 references
    THE BIOTECH COMPANY IS INNOVATIVE AND EFFECTIVE MONOCLONAL ANTIBODIES FOR OWN ACCOUNT AND FOR HIRE OR REWARD. ALTHOUGH HIGHLY COMPETITIVE IN VACCINATION PROTOCOLS, THE CURRENT PROCESS LACKS A ROBOTIC SYSTEM FOR (English)
    0 references
    LA SOCIÉTÉ DE BIOTECHNOLOGIE TAKIS PRODUIT DES ANTICORPS MONOCLONAUX INNOVANTS ET EFFICACES POUR SON PROPRE COMPTE ET POUR LE COMPTE DE TIERS. BIEN QUE TRÈS COMPÉTITIF DANS LES PROTOCOLES DE VACCINATION, LE PROCESSUS ACTUEL NE DISPOSE PAS D’UN SYSTÈME ROBOTISÉ POUR (French)
    point in time
    16 December 2021
    0 references
    TAKIS BIOTECHNOLOGIE BEDRIJF PRODUCEERT INNOVATIEVE EN EFFECTIEVE MONOKLONALE ANTILICHAMEN OP EIGEN EN VOOR REKENING VAN DERDEN. HOEWEL ZEER CONCURREREND IN VACCINATIEPROTOCOLLEN, ONTBREEKT HET HUIDIGE PROCES AAN EEN GEROBOTISEERD SYSTEEM VOOR (Dutch)
    point in time
    23 December 2021
    0 references
    TAKIS BIOTECHNOLOGIE-UNTERNEHMEN PRODUZIERT INNOVATIVE UND EFFEKTIVE MONOKLONALE ANTIKÖRPER FÜR SICH ALLEIN UND IM AUFTRAG DRITTER. OBWOHL IN DEN IMPFPROTOKOLLEN SEHR KONKURRENZFÄHIG IST, FEHLT DEM DERZEITIGEN PROZESS EIN ROBOTERSYSTEM FÜR (German)
    point in time
    24 December 2021
    0 references
    LA EMPRESA BIOTECNOLÓGICA TAKIS PRODUCE ANTICUERPOS MONOCLONALES INNOVADORES Y EFICACES POR SÍ SOLOS Y EN NOMBRE DE TERCEROS. AUNQUE MUY COMPETITIVO EN LOS PROTOCOLOS DE VACUNACIÓN, EL PROCESO ACTUAL CARECE DE UN SISTEMA ROBOTIZADO PARA (Spanish)
    point in time
    25 January 2022
    0 references
    location (string)
    ROMA
    0 references

    Identifiers

    Italian Unique Project Code
    F83G17000640007
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q2035396&oldid=27872554"